During 2019 EpiTech concluded it’s 1st human clinical trial, treating a total of 29 moderate to severe dry eye disease patients in a multicenter study in 3 sites.
Trial results were excellent, showcasing a response rate that is far above current industry standards with clinically significant improvement in both signs and symptoms. The treatment also showed a significant reduction in lubricant consumption by the trial participants, as much as 50%.

EpiTech is now analyzing the final results and a 2nd multicenter human clinical trial will begin within the following weeks.